Tarsus Pharmaceuticals (TARS) Set to Announce Quarterly Earnings on Wednesday

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) will issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($1.15) per share for the quarter.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($1.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.06. The business had revenue of $13.08 million for the quarter, compared to analysts' expectations of $4.63 million. During the same quarter in the prior year, the firm earned ($0.49) earnings per share. On average, analysts expect Tarsus Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Tarsus Pharmaceuticals Stock Up 6.6 %

Shares of TARS stock traded up $2.14 on Thursday, hitting $34.63. The stock had a trading volume of 446,461 shares, compared to its average volume of 711,941. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -7.46 and a beta of 1.11. The stock's 50 day moving average is $34.12 and its 200-day moving average is $25.27. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.93. Tarsus Pharmaceuticals has a 52-week low of $12.57 and a 52-week high of $40.40.

Insider Buying and Selling

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 10,415 shares of the firm's stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $318,699.00. Following the transaction, the chief executive officer now owns 26,456 shares of the company's stock, valued at approximately $809,553.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Tarsus Pharmaceuticals news, COO Seshadri Neervannan sold 4,879 shares of the firm's stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $149,297.40. Following the transaction, the chief operating officer now owns 64,767 shares of the company's stock, valued at approximately $1,981,870.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Bobak R. Azamian sold 10,415 shares of the firm's stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $318,699.00. Following the transaction, the chief executive officer now owns 26,456 shares of the company's stock, valued at approximately $809,553.60. The disclosure for this sale can be found here. Insiders have sold a total of 24,496 shares of company stock valued at $749,578 in the last quarter. Company insiders own 11.54% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on TARS shares. HC Wainwright upped their target price on shares of Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the company a "buy" rating in a research note on Wednesday, February 28th. Jefferies Financial Group increased their price objective on shares of Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the company a "buy" rating in a research note on Wednesday, March 6th. Oppenheimer reiterated an "outperform" rating and set a $59.00 price objective (up from $55.00) on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 28th. The Goldman Sachs Group increased their target price on shares of Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the stock a "neutral" rating in a report on Thursday, February 29th. Finally, Barclays increased their target price on shares of Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the stock an "overweight" rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Tarsus Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $48.38.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.